English cross-cultural translation and validation of the NM-Score: a system for motor function classification in patients with neuromuscular diseases
Vuillerot C, Meilleur KG, Jain M, Waite M, Wu T, Linton M, Datsgir J, Donkervoort S, Leach ME, Rutkowski A, Rippert P, Payan C, Iwaz J, Hamroun D, Bérard C, Poirot I, Bönnemann CG.
Arch Phys Med Rehabil. 2014. 95(11):2064-2070.e1.
Developement of an English version of the NM-Score. Its concurrent validity was tested in 42 patients aged 5 to 19 years old with a confirmed or suspected diagnosis of congenital muscular dystrophy against criterion standards (Brooke, MFM, Activlim, Jebsen Test, and myometry). Informant agreements between patient-reported and clinician-reported NM-Score were measured by weighted Kappa. Significant correlation coefficients were found between NM-Score and criterion standards MFM D1, Activlim and Hip abduction. Informant agreements between clinician- and patient-reported NM scores were excellent for D1 but moderate for D2 and D3. The English version is thus a reliable and valid instrument that can be used in clinical practice and research to describe the functional abilities of patients with neuromuscular diseases.
Keywords: Neuromuscular diseases, activities of daily living, disability evaluation, rehabilitation
Articles dans les revues scientifiques
The Use of the Gait Profile Score and Gait Variable Score in Individuals With Duchenne Muscular Dystrophy
de Souza MA, Cezarani A, Lizzi EAD, Davoli GBQ, Mattiello SM, Jones R, Mattiello-Sverzut AC J Biomech. 2020. 98, 109485. Study of the applicability of the Gait Deviation Index (GDI) and the Gait Profile Score (GPS) in patients with duchenne Muscular Dystrophy, using...
Analysis of Different Device Interactions in a Virtual Reality Task in Individuals With Duchenne Muscular Dystrophy-A Randomized Controlled Trial
de Freitas BL, da Silva TD, Crocetta TB, Massetti T, de Araújo LV, Coe S, Dawes H, Caromano FA, Monteiro CBM. Front Neurol. 2019 Jan 29;10:24. The aim of the study was to compare performance of patients with Duchenne Muscular Dystrophy to perform a virtual task using...
Longitudinal reliability of outcome measures in patients with Duchenne muscular dystrophy.
Nagy S, Schädelin S, Hafner P, Bonati U, Scherrer D, Ebi S, Schmidt S, Orsini AL, Bieri O, Fischer D. Muscle Nerve. 2020. 61(1), 63-68. In this retrospective study, the longitudinal reliability of clinical and radiological endpoints in 29 ambulant patients with DMD...
Longitudinal changes in clinical outcome measures in COL6-related dystrophies and LAMA2-related dystrophies.
Jain MS, Meilleur K, Kim E, Norato G, Waite M, Nelson L, McGuire M, Duong T, Keller K, Lott DJ, Glanzman A, Rose K, Main M, Fiorini C, Chrismer I, Linton M, Punjabi M, Elliott J, Tounkara F, Vasavada R, Logaraj R, Winkert J, Donkervoort S, Leach M, Dastgir J, Hynan L,...
Effect of Combination l-Citrulline and Metformin Treatment on Motor Function in Patients With Duchenne Muscular Dystrophy: A Randomized Clinical Trial
Hafner P, Bonati U, Klein A, Rubino D, Gocheva V, Schmidt S, Schroeder J, Bernert G, Laugel V, Steinlin M, Capone A, Gloor M, Bieri O, Hemkens LG, Speich B, Zumbrunn T, Gueven N, Fischer D. JAMA Netw Open. 2019. 2;2(10):e1914171. Results of a single-center randomized...
Tamoxifen in Duchenne muscular dystrophy (TAMDMD): study protocol for a multicenter, randomized, placebo-controlled, double-blind phase 3 trial.
Nagy S, Hafner P, Schmidt S, Rubino-Nacht D, Schädelin S, Bieri O, Fischer D. Trials. 2019. 20(1), 637. Protocol of a multicenter, randomized, double-blind, placebo-controlled phase III trial study aiming to demonstrate safety and efficacy of tamoxifen over placebo in...